The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
- PMID: 30482910
- DOI: 10.1038/s41575-018-0082-x
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Abstract
Nonalcoholic fatty liver disease (NAFLD) and its inflammatory and often progressive subtype nonalcoholic steatohepatitis (NASH) are becoming the leading cause of liver-related morbidity and mortality worldwide, and a primary indication for liver transplantation. The pathophysiology of NASH is multifactorial and not yet completely understood; however, innate immunity is a major contributing factor in which liver-resident macrophages (Kupffer cells) and recruited macrophages play a central part in disease progression. In this Review, we assess the evidence for macrophage involvement in the development of steatosis, inflammation and fibrosis in NASH. In this process, not only the polarization of liver macrophages towards a pro-inflammatory phenotype is important, but adipose tissue macrophages, especially in the visceral compartment, also contribute to disease severity and insulin resistance. Macrophage activation is mediated by factors such as endotoxins and translocated bacteria owing to increased intestinal permeability, factors released from damaged or lipoapoptotic hepatocytes, as well as alterations in gut microbiota and defined nutritional components, including certain free fatty acids, cholesterol and their metabolites. Reflecting the important role of macrophages in NASH, we also review studies investigating drugs that target macrophage recruitment to the liver, macrophage polarization and their inflammatory effects as potential treatment options for patients with NASH.
Similar articles
-
Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.Clin Liver Dis. 2018 Feb;22(1):23-37. doi: 10.1016/j.cld.2017.08.007. Epub 2017 Oct 18. Clin Liver Dis. 2018. PMID: 29128059 Review.
-
Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?Expert Rev Gastroenterol Hepatol. 2021 Jan;15(1):51-64. doi: 10.1080/17474124.2020.1817740. Epub 2020 Sep 17. Expert Rev Gastroenterol Hepatol. 2021. PMID: 32878486
-
Natural products that target macrophages in treating non-alcoholic steatohepatitis.World J Gastroenterol. 2020 May 14;26(18):2155-2165. doi: 10.3748/wjg.v26.i18.2155. World J Gastroenterol. 2020. PMID: 32476782 Free PMC article. Review.
-
Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.Nutrients. 2017 Apr 14;9(4):387. doi: 10.3390/nu9040387. Nutrients. 2017. PMID: 28420094 Free PMC article. Review.
-
Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.Int J Mol Sci. 2021 Jul 27;22(15):8008. doi: 10.3390/ijms22158008. Int J Mol Sci. 2021. PMID: 34360773 Free PMC article. Review.
Cited by
-
Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.Sci Rep. 2021 Jun 3;11(1):11709. doi: 10.1038/s41598-021-91187-2. Sci Rep. 2021. PMID: 34083664 Free PMC article.
-
Myeloid Nrf2 deficiency aggravates non-alcoholic steatohepatitis progression by regulating YAP-mediated NLRP3 inflammasome signaling.iScience. 2021 Apr 16;24(5):102427. doi: 10.1016/j.isci.2021.102427. eCollection 2021 May 21. iScience. 2021. PMID: 34041450 Free PMC article.
-
Role of Indole-3-Acetic Acid in NAFLD Amelioration After Sleeve Gastrectomy.Obes Surg. 2021 Jul;31(7):3040-3052. doi: 10.1007/s11695-021-05321-0. Epub 2021 May 10. Obes Surg. 2021. PMID: 33973136
-
Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics.Livers. 2024 Sep;4(3):455-478. doi: 10.3390/livers4030033. Epub 2024 Sep 13. Livers. 2024. PMID: 39328386 Free PMC article.
-
Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications.Front Immunol. 2024 Jan 30;15:1336493. doi: 10.3389/fimmu.2024.1336493. eCollection 2024. Front Immunol. 2024. PMID: 38352880 Free PMC article. Review.
References
-
- Vernon, G., Baranova, A. & Younossi, Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274–285 (2011). - PubMed
-
- Wong, R. J. et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148, 547–555 (2015). - PubMed
-
- Schuppan, D., Surabattula, R. & Wang, X. Y. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238–250 (2018). This comprehensive review provides an insight into the epidemiology, key mechanisms, diagnostic tools and treatment options for liver fibrosis in NAFLD. - PubMed
-
- Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836–1846 (2010). - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical